|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0023884,
umls-concept:C0039194,
umls-concept:C0042210,
umls-concept:C0085358,
umls-concept:C0085862,
umls-concept:C0205314,
umls-concept:C0591833,
umls-concept:C0679622,
umls-concept:C0871261,
umls-concept:C1299583,
umls-concept:C1332717,
umls-concept:C1413244,
umls-concept:C1549571,
umls-concept:C1552861,
umls-concept:C1608386,
umls-concept:C1704632,
umls-concept:C1706438,
umls-concept:C1706817,
umls-concept:C2698600,
umls-concept:C2911692
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2004-9-15
|
|
pubmed:abstractText |
Vaccines for the prophylactic and/or therapeutic immunization against hepatotropic pathogens (e.g., hepatitis B and hepatitis C virus) should establish long-lasting, specific antiviral effector/memory CD8+ T cell immunity in the liver. We describe a novel peptide-based vaccine in which antigenic major histocompatibility complex Class I-binding peptides are fused to a cationic (e.g., human immunodeficiency virus tat-derived) domain and complexed to immune-stimulating oligonucleotides. This vaccine formulation efficiently primes liver-homing, Class I-restricted CD8+ effector/memory T cell responses. In different antigen systems, this formulation was more potent in priming liver-homing CD8+ T cell responses than DNA-based vaccines delivering the same epitopes. CD8+ T cell priming was independent of CD4+ T cell "help" but submitted to regulatory control by CD25+ CD4+ T cells. The vaccine efficiently primed memory/effector CD8+ T cells detectable in the liver for more than 3 months after a single injection. With increasing time after priming, the phenotype of these specific memory CD8+ T cells shifted from an effector memory to a central memory type. The vaccine could override T cell tolerance in mice expressing the relevant antigen from a transgene in the liver. The CD8+ T cell immunity in the liver primed by this peptide formulation could be boosted by challenge injections. In conclusion, we describe a simple and potent vaccine formulation that has the potential to generate or reconstitute specific CD8+ T cell immunity to hepatotropic pathogens in the liver.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
0270-9139
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright 2004 American Association for the Study of Liver Diseases
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
40
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
300-9
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:15368434-Animals,
pubmed-meshheading:15368434-CD4-Positive T-Lymphocytes,
pubmed-meshheading:15368434-CD8-Positive T-Lymphocytes,
pubmed-meshheading:15368434-Cations,
pubmed-meshheading:15368434-Epitopes,
pubmed-meshheading:15368434-Hepatitis B Surface Antigens,
pubmed-meshheading:15368434-Hepatitis B virus,
pubmed-meshheading:15368434-Histocompatibility Antigens Class I,
pubmed-meshheading:15368434-Immune Tolerance,
pubmed-meshheading:15368434-Immunity, Cellular,
pubmed-meshheading:15368434-Immunization, Secondary,
pubmed-meshheading:15368434-Immunologic Memory,
pubmed-meshheading:15368434-Liver,
pubmed-meshheading:15368434-Mice,
pubmed-meshheading:15368434-Mice, Inbred C57BL,
pubmed-meshheading:15368434-Mice, Knockout,
pubmed-meshheading:15368434-Oligonucleotides,
pubmed-meshheading:15368434-Phenotype,
pubmed-meshheading:15368434-Receptors, Interleukin-2,
pubmed-meshheading:15368434-Recombination, Genetic,
pubmed-meshheading:15368434-Time Factors,
pubmed-meshheading:15368434-Vaccines, Subunit,
pubmed-meshheading:15368434-Viral Hepatitis Vaccines
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
Novel peptide-based vaccines efficiently prime murine "help"-independent CD8+ T cell responses in the liver.
|
|
pubmed:affiliation |
Department of Medical Microbiology and Immunology, University of Ulm, Ulm, Germany. nektarios.dikopoulos@medizin.uni-ulm.de
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
